Bank of America
RGNX icon

Bank of America’s Regenxbio RGNX Stock Holding History

Bank of America’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.72M Buy
324,860
+24,251
+8% +$255K ﹤0.01% 3902
2025
Q4 		$4.33M Sell
300,609
-114,697
-28% -$1.43M ﹤0.01% 3500
2025
Q3 		$4.01M Sell
415,306
-157,193
-27% -$1.39M ﹤0.01% 4215
2025
Q2 		$4.7M Sell
572,499
-79,444
-12% -$665K ﹤0.01% 3969
2025
Q1 		$4.66M Buy
651,943
+370,739
+132% +$2.76M ﹤0.01% 3873
2024
Q4 		$2.17M Sell
281,204
-164,980
-37% -$1.55M ﹤0.01% 4371
2024
Q3 		$4.68M Buy
446,184
+249,697
+127% +$3.04M ﹤0.01% 3793
2024
Q2 		$2.3M Buy
196,487
+33,788
+21% +$526K ﹤0.01% 4337
2024
Q1 		$3.43M Buy
162,699
+29,951
+23% +$533K ﹤0.01% 3987
2023
Q4 		$2.38M Sell
132,748
-25,867
-16% -$456K ﹤0.01% 4224
2023
Q3 		$2.61M Buy
158,615
+24,151
+18% +$438K ﹤0.01% 4016
2023
Q2 		$2.69M Sell
134,464
-63,786
-32% -$1.23M ﹤0.01% 3948
2023
Q1 		$3.75M Buy
198,250
+32,234
+19% +$713K ﹤0.01% 3798
2022
Q4 		$3.77M Buy
166,016
+31,517
+23% +$712K ﹤0.01% 3662
2022
Q3 		$3.55M Buy
134,499
+94,212
+234% +$2.8M ﹤0.01% 3699
2022
Q2 		$995K Sell
40,287
-135,907
-77% -$3.4M ﹤0.01% 4916
2022
Q1 		$5.85M Buy
176,194
+53,240
+43% +$1.48M ﹤0.01% 3457
2021
Q4 		$4.02M Buy
122,954
+75,246
+158% +$2.56M ﹤0.01% 3877
2021
Q3 		$2M Sell
47,708
-8,843
-16% -$318K ﹤0.01% 4445
2021
Q2 		$2.2M Sell
56,551
-95,809
-63% -$3.43M ﹤0.01% 4240
2021
Q1 		$5.2M Buy
152,360
+73,243
+93% +$3.12M ﹤0.01% 3357
2020
Q4 		$3.59M Buy
79,117
+5,846
+8% +$204K ﹤0.01% 3442
2020
Q3 		$2.02M Sell
73,271
-49,591
-40% -$1.62M ﹤0.01% 3675
2020
Q2 		$4.53M Buy
122,862
+100,220
+443% +$3.74M ﹤0.01% 2916
2020
Q1 		$733K Sell
22,642
-3,643
-14% -$152K ﹤0.01% 4221
2019
Q4 		$1.08M Sell
26,285
-5,387
-17% -$213K ﹤0.01% 4454
2019
Q3 		$1.13M Sell
31,672
-76,645
-71% -$3.11M ﹤0.01% 4472
2019
Q2 		$5.57M Buy
108,317
+7,126
+7% +$356K ﹤0.01% 3129
2019
Q1 		$5.8M Buy
101,191
+31,944
+46% +$1.58M ﹤0.01% 3020
2018
Q4 		$2.9M Buy
69,247
+17,183
+33% +$1.01M ﹤0.01% 3529
2018
Q3 		$3.93M Sell
52,064
-13,756
-21% -$991K ﹤0.01% 3423
2018
Q2 		$4.72M Buy
65,820
+9,938
+18% +$475K ﹤0.01% 3209
2018
Q1 		$1.67M Sell
55,882
-39,890
-42% -$1.16M ﹤0.01% 4015
2017
Q4 		$3.19M Buy
95,772
+26,624
+39% +$802K ﹤0.01% 3540
2017
Q3 		$2.28M Buy
69,148
+16,366
+31% +$368K ﹤0.01% 3875
2017
Q2 		$1.04M Buy
52,782
+1,402
+3% +$27.1K ﹤0.01% 4410
2017
Q1 		$992K Buy
51,380
+597
+1% +$11.5K ﹤0.01% 4433
2016
Q4 		$942K Sell
50,783
-3,955
-7% -$75.6K ﹤0.01% 4395
2016
Q3 		$767K Buy
54,738
+36,379
+198% +$401K ﹤0.01% 4341
2016
Q2 		$147K Buy
18,359
+16,139
+727% +$179K ﹤0.01% 5360
2016
Q1 		$24K Buy
2,220
+1,270
+134% +$16.3K ﹤0.01% 6065
2015
Q4 		$16K Buy
950
+765
+414% +$15.2K ﹤0.01% 6514
2015
Q3 		$4K Buy
+185
New +$4.72K ﹤0.01% 6835

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's RGNX Position: Q1 2026 in Review

Bank of America increased its Regenxbio (RGNX) stake by 8.1% in Q1 2026, buying an estimated $255K and bringing the position to 324,860 shares worth $2.72M. The position accounts for ﹤0.01% of the portfolio, ranked #3902.

Bank of America first reported a position in RGNX in Q3 2015 and has held it in 43 quarters since. The position peaked at $5.85M in Q1 2022. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Bank of America held 324,860 shares of Regenxbio worth $2.72M as of Q1 2026.
  • Bank of America bought 24,251 Regenxbio shares in Q1 2026, an estimated $255K.
  • Regenxbio made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3902 holding.
  • Bank of America first reported a position in Regenxbio in Q3 2015 and has held it in 43 quarters since.
  • Bank of America's Regenxbio position peaked at $5.85M in Q1 2022.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.